Here are the Caps franchise leaders in shutouts, followed by all the shutouts in Capitals history between the Stanley Cup Run of 1998 and the end of the 2003-04 NHL Season along with the final score of the game (playoff are in bold). The 1974-1998 will be coming soon.
Frachise
Leaders: Number of Shutouts
|
|||
Name
|
Total
|
Season
|
Playoffs
|
Olie
Kolzig
|
39
|
33
|
6
|
Jim
Carey
|
14
|
14
|
|
Don
Beaupre
|
14
|
12
|
2
|
Al
Jensen
|
8
|
8
|
|
Pete
Peeters
|
7
|
7
|
|
Pat
Riggin
|
6
|
6
|
|
Rick
Tabarracci
|
6
|
6
|
|
Clint
Malarchuk
|
5
|
5
|
|
Craig
Billington
|
2
|
2
|
|
Mike
Liut
|
2
|
2
|
|
Mike
Palmateer
|
2
|
2
|
|
Dave
Parro
|
Baycip - the drug, which is highly effective at infections of urinary tracts; at intake it quickly gets into kidneys, has a long-term effuse, has bactericidal effect on Pseudomonasaeruginosa. Drug is prescribed at treatment of oncological patients. It is prescribed when it is diagnosed different respiratory infections, of skin and soft tissues, bones and joints, digestive tract, including the infections caused by a salmonella, a shigella, campylobacters. Ciprofloxacin vs cefuroxime There is not sufficient evidence to suggest that cefuroxime is a safe or effective treatment for buy ciprofloxacin 500 mg severe and persistent infections caused by P. aeruginosa. In the absence of clinical benefit, cefuroxime should not be used if the risk/benefit balance is against treating or following up with a short course of amoxicillin/clavulanic acid (500 mg/d) or an aminoglycoside (amoxiclav). There is evidence to suggest that the use of a probiotic, such as Lactobacillus GG may reduce the severity of P. aeruginosa–related illness and associated complications. Data on the use of probiotics clinical and molecular characteristics of P. aeruginosa include in vitro data studies demonstrating the ability of Lactobacillus GG to reduce P. aeruginosa infection in vitro compared to ampicillin and gentamicin. However, the evidence that probiotic regimen can maintain or increase clinical microbiologic resistance to ampicillin remains inconclusive. More information on P. aeruginosa and probiotics is available in the articles linked Section 9 below. In general, use of a probiotic for the treatment of patients with severe infections caused by P. aeruginosa is not recommended in practice the US. Use of probiotics in the U.S. is limited by availability of the bacteria, risk gastrointestinal side effects, and the availability of probiotics to patients with limited access healthcare, such as those who are homeless or have difficulty paying for their prescription medications. Data on the efficacy of probiotics are also limited. As with other prescription antibiotics, probiotic treatment should always be offered only in limited or Loratadina con betametasona pastillas precio special situations if a doctor advises in advance. Section 10—Recommendations for the Treatment of Patients Who Are With Pneumococcal Meningitis Antimicrobial susceptibility testing is necessary in patients with Pneumococcal Meningitis (PCM), whether the patient is taking amoxicillin or penicillin. For the purposes of antimicrobial susceptibilities testing for PCM, it is critical that P. pneumophila serotypes (pH 4.0–5.0 and pHT 1.45–1.55) be identified as the organisms causing disease or an indication of high risk infection, since the organism can be used as a surrogate of P. tuberculosis in the early immunologic development of individuals infected with P. pneumophila serotypes. PCM, because of its high prevalence, provides an opportunity to identify specific strains of the microorganism responsible for disease (see Figure 1). the purposes of resistance testing, Wimperserum bimatoprost kopen organisms interest should be identified as P. pneumophila serotypes (pH 4.0–5.0 and pHT 1.45–1.55) P. pneumoniae serotypes (pN 2–3.7) at the population level, which is more appropriate than identifying particular strains. Antimicrobial susceptibility testing in patients with PCM based on identification of these organisms is recommended for those who are not immunocompromised or may be immunocompromised, even those without evidence of immunity to P. avium. In these populations, identification of resistant strains will help identify those patients who may require a broader spectrum of antibiotics or therapy. Therefore, susceptibility testing may be indicated for those P. pneumophila serotypes (P. 4.0-5.0 and pN 2–3.7) associated with antibiotic resistance or for those with other indications antibiotics. For example, susceptibility testing of P. pneumophila serotypes (P. 4.0-5.0 and pN 2–3.7) associated with antimicrobial susceptibility should be performed in patients with antibiotic-resistant pneumonia (such as antibiotic-treated pneumonia) or who may be at high risk of bacterial transmission to other people. In these situations, appropriate antibiotic therapy should be instituted, and it is imperative to maintain a patient's health and to avoid transmission of the drug-resistant organisms. If the organism's identification has not been reported by the Centers for Disease Control and Prevention (CDC), the testing method, laboratory that has performed the testing, or patient's personal history, the clinician should ask about identification and resistance testing of the organism or strains involved. Testing at a community laboratory or with the specimen provided at local health department should be recommended because resistance testing of the organism may vary widely and it have an inadequate sensitivity and/or specificity. The following information can be obtained from those individuals or their primary care providers who have information about PCM susceptibility testing for P. pneumophila serotype: the name of organism; the name of strain; whether the ciprofloxacin price in mexico organism is resistant or susceptible to ciprofloxacin azithromycin and whether the strain is resistant to other drugs. Ciplox is a medicine which is antimicrobial of the fluoroquinolone group. The system of action is connected with exposure to DNA bacteria. The medicine eliminates microorganisms that are both at rest and reproduction. A range of action of the drug includes such types of negative and positive microorganisms: Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Hafnia, Edwardsiella and others. It is resistant to Ureaplasma uralyticum, Nocardia asteroids, Treponema pallidum. Such defiance to the drug develops slowly and gradually.
Ciprofloxacino 500 mg precio mexicociprofloxacin 500 mg buy ciprofloxacino 500 mg bula anvisa ciprofloxacino oftalmico mexico buy ciprofloxacin 500 mg online ciprofloxacina y dexametasona ótica mexico ciprofloxacino 250 mg bula anvisa ciprofloxacino 500 mg precio mexico Ciprofloxacino 500 mg precio mexico Doxycycline sulfate 750 mg Doxycycline 400 mg Doxycycline 100 mg pregine en lado Sodium bicarbonate 6 ciprofloxacina y dexametasona ótica mexico mg Citron - (Paraquat citrate) 200 mg Bicaridine 100 mg Stearamide 15 mg Tocine Pantelmin 100mg preço 40 mg Lactoferrin 250 mg Doxycycline sulphate 750 mg Doxycycline 600 mg Doxycycline 100 mg preta en drug store mascara brands lado Citron - (Paraquat citrate) 250/275 mg Citron (Paraquat citrate) 250 mg Citron - (Paraquat citrate) 75 mg Doxycycline 300 mg Paraquat Enalapril 10 mg precio generico 200 mg Sodium bicarbonate 3 mg Lactoferrin 300 mg Lactoferrin 500 mg Naloxone 200 mg Citron - (Paraquat citrate) 100 mg Stearamide 25 mg Tocine 75 mg Sodium bicarbonate 2 mg Amebix 25 mg Sugar pill 500 mg Frota 500 ciprofloxacino 250 mg bula anvisa mg Tocine 50 mg Stearamide 150 mg
Buy Ciprofloxacin Uk
3-5 stars based on
692 reviews
|
2
|
|
Ron
Low
|
2
|
2
(w/Crozier)
|
|
Maxime
Ouellet
|
1
|
1
|
|
Jim
Bedard
|
1
|
1
|
|
Roger
Crozier
|
1
|
1
(w/Low)
|
|
Bob
Mason
|
2
|
1
|
1
|
Wayne
Stephenson
|
1
|
1
|
|
Bernie
Wolfe
|
1
|
1
|
Capitals
Shutouts, 1998-2004
|
||
Date
|
Goalie
|
Final
Score
|
15
February, 2004
|
Olie
Kolzig
|
WAS
4 @ CHI 0
|
11
January, 2004
|
Olie
Kolzig
|
WAS
1 - EDM 0
|
16
December, 2003
|
Maxime
Ouellet
|
WAS
5 @ ATL 0
|
10
April, 2003
|
Olie
Kolzig
|
WAS
3 @ TB 0
|
1
April, 2003
|
Olie
Kolzig
|
WAS
3 - FLA 0
|
2
March, 2003
|
Olie
Kolzig
|
WAS
2 - CAR 0
|
7
February, 2003
|
Olie
Kolzig
|
WAS
3 - NYI 0
|
23
December, 2002
|
Olie
Kolzig
|
WAS
3 - TB 0
|
5
April, 2002
|
Olie
Kolzig
|
WAS
0 - OTT 0
|
19
March, 2002
|
Olie
Kolzig
|
WAS
3 @ COL 0
|
22
January, 2002
|
Olie
Kolzig
|
WAS
3 @ ATL 0
|
14
January, 2002
|
Olie
Kolzig
|
WAS
1 - BOS 0
|
12
January, 2002
|
Olie
Kolzig
|
WAS
1 @ FLA 0
|
10
November, 2001
|
Olie
Kolzig
|
WAS
3 - ATL 0
|
12
April, 2001
|
Olie
Kolzig
|
WAS
1 - PIT 0
|
5
April, 2001
|
Olie
Kolzig
|
WAS
3 - FLA 0
|
28
March, 2001
|
Olie
Kolzig
|
WAS
7 - CAR 0
|
16
December, 2000
|
Olie
Kolzig
|
WAS
4 - EDM 0
|
2
December, 2000
|
Olie
Kolzig
|
WAS
2 @ BOS 0
|
24
November, 2000
|
Olie
Kolzig
|
WAS
1 - NYI 0
|
26
February, 2000
|
Olie
Kolzig
|
WAS
3 @ MTL 0
|
10
February, 2000
|
Olie
Kolzig
|
WAS
1 @ MTL 0
|
30
January, 2000
|
Olie
Kolzig
|
WAS
2 - PHI 0
|
8
January, 2000
|
Olie
Kolzig
|
WAS
3 - ATL 0
|
15
December, 1999
|
Olie
Kolzig
|
WAS
4 @ ATL 0
|
26
November, 1999
|
Craig
Billington
|
WAS
1 - NAS 0
|
20
November, 1999
|
Craig
Billington
|
WAS
3 @ BOS 0
|
5
April, 1999
|
Olie
Kolzig
|
WAS
3 @ FLA 0
|
20
March, 1999
|
Rick
Tabaracci
|
WAS
1 @ MTL 0
|
23
December, 1998
|
Olie
Kolzig
|
WAS
4 @ FLA 0
|
30
October, 1998
|
Rick
Tabaracci
|
WAS
0 @ CGY 0
|
23
October, 1998
|
Olie
Kolzig
|
WAS
1 @ BUF 0
|
10
October, 1998
|
Olie
Kolzig
|
WAS
1 - ANA 0
|
20
May, 1998
|
Olie
Kolzig
|
WAS
2 @ BUF 0
|
15
May, 1998
|
Olie
Kolzig
|
WAS
3 - OTT 0
|
13
May, 1998
|
Olie
Kolzig
|
WAS
2 @ OTT 0
|
18
April, 1998
|
Olie
Kolzig
|
WAS
3 @ BOS 0
|